Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab

BACKGROUND: Lenvatinib plus pembrolizumab showed significantly improved progression-free and overall survival outcomes compared with sunitinib in patients with advanced renal cell carcinoma in the CLEAR study (NCT02811861). Here, we used CLEAR data to characterize common adverse reactions (ARs; adve...

Descripción completa

Detalles Bibliográficos
Autores principales: Motzer, Robert, George, Saby, Merchan, Jaime R, Hutson, Thomas E, Song, Xun, Perini, Rodolfo F, Xie, Ran, Bapat, Urmi, Puente, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Genitourinary Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243770/
https://www.ncbi.nlm.nih.gov/pubmed/36866412
http://dx.doi.org/10.1093/oncolo/oyac269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243770/
https://www.ncbi.nlm.nih.gov/pubmed/36866412
http://dx.doi.org/10.1093/oncolo/oyac269

Ejemplares similares